Keep up to date with the latest news from Cellzome
News releases are PDF files

December 2011: Cellzome awarded UK's Technology Strategy Board grant as part of the Regenerative Medicine Programme

December 2011: Cellzome Founder wins EU Women Innovators Award. Dr. Gitte Neubauer awarded first prize for the foundation of Cellzome

October 2011: Proteomic Study Published in the Journal Nature Paves the Way for New Treatment for Incurable Leukaemia Using an Epigenetic Inhibitor

September 2011: Cellzome Achieves Clinical Candidate Milestone from Inflammation Alliance
with GlaxoSmithKline

December 2011: Cellzome awarded UK's Technology Strategy Board grant as part of the Regenerative Medicine Programme

December 2011: Cellzome Founder wins EU Women Innovators Award. Dr. Gitte Neubauer awarded first prize for the foundation of Cellzome

October 2011: Proteomic Study Published in the Journal Nature Paves the Way for New Treatment for Incurable Leukaemia Using an Epigenetic Inhibitor

September 2011: Cellzome Achieves Clinical Candidate Milestone from Inflammation Alliance
with GlaxoSmithKline

August 2011: Cellzome publishes discovery of novel and selective inhibitors of Parkinson's disease kinase LRRK2

May 2011: Cellzome to Study Epigenetic Factors with Neusentis

February 2011: Cellzome Builds Scientific Advisory Board with World-Leading Experts in Proteomics, Epigenetics and Immunology

February 2011: Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK

January 2011: Cellzome publication demonstrates utility of Episphere™ technology

December 2010: Cellzome announces Achievement of First Milestone in Epigenetics Collaboration with GSK

December 2010: Cellzome further builds out preclinical capability with industry experienced hires

October 2010: Cellzome publication demonstrates utility of chemical proteomics approach for drug profiling in patient material

October 2010: Cellzome sponsors Focus on Epigenetics issue in Nature Biotechnology.

October 2010: Cellzome Appoints Prof. Tony Kouzarides and Dr Peter Machin to Scientific Advisory Board

September 2010: Asterand's Subsidiary BioSeek Signs Agreement with Cellzome

September 2010: Cellzome hires Vice President Therapeutics to strengthen Preclinical Capabilities

September 2010: Cellzome's CEO Tim Edwards new Chairman of UK's BioIndustry Association

June 2010: SYN|thesis med chem Pty to provide medicinal and computational chemistry services to Cellzome

March 2010: Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease

Coverage of this press release in BioCentury

November 2009: Cellzome Advances Understanding of Hepatitis C

September 2009: Cellzome Announces Achievement of Fourth Milestones in Inflammation Alliance with GlaxoSmithKline

September 2009: Cellzome technology used to unravel novel regulatory mechanism in cancer signaling pathway

March 2009: Cellzome Announces Achievement of Second and Third Milestones in Inflammation Alliance with GlaxoSmithKline

December 2008: Cellzome Announces Achievement of First Milestone in Inflammation Alliance with GlaxoSmithKline

November 2008: Cellzome awarded € 3.85m grant in Germany's High-Tech Initiative to Fund Top Regional Clusters

October 2008: Translational medicine award to use Kinobeads™ to profile the expressed kinome in early inflammatory arthritis

September 2008: Cellzome Strengthens Management Team with New Hires from UCB Celltech

September 2008: GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

July 2008: Cellzome extends Drug Discovery Collaboration

April 2008: TAP Technology Originators nominated for title of European Inventor of the Year 2008

January 2008: Cellzome appoints Dr. Jane Dancer as VP Business Development

December 2007: Cellzome Establishes Scientific Advisory Board

November 2007: Cellzome CEO appointed to the Board of the UK's BioIndustry Association

August 2007: Cellzome publishes a Powerful 'Finger-Printing' Technology which Identifies Novel Targets for Gleevec™

March 2007: Cellzome Receives First Milestone Payment for Alzheimer's Programme from Ortho-McNeil Pharmaceutical, Inc.

January 2007: Cellzome Announces Extension of Drug Discovery Collaboration in Alzheimer's Disease with Ortho-McNeil Pharmaceutical, Inc.

January 2007: Cellzome scientists publish novel approach to quantitative proteomics in Nature Biotechnology

October 2006: Cellzome Announces further Extension of Molecular Pathway Collaboration

July 2006: Galapagos and Cellzome in kinase drug discovery collaboration

July 2006: Cellzome announces Extension of Molecular Pathway Collaboration

July 2006: Cellzome appoints David Simmons as Chief Scientific Officer

January 2006: Cellzome and EMBL scientists publish the first genome-wide surveyof protein complexes

October 2005: Cellzome and Graffinity awarded € 2.2 million grant fromGerman Ministry of Research and Education

September 2005: Cellzome Concludes Collaboration with Bayer HealthCare

July 2005: Expansion of Pathway Collaboration with Novartis

May 2005: Ortho-McNeil Pharmaceutical exercises option to license Alzheimer's disease compounds

March 2005: Drug Discovery Collaboration in Alzheimer's Disease with Ortho-McNeil Pharmaceutical

September 2004: Partnership Agreement with Novartis

September 2004: Tim Edwards joins Cellzome as CEO

March 2004: Cellzome Moves UK Facilities to Cambridge, One of Europe’s Biggest Biotech Hubs

February 2004: A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nature Cell Biology Vol. 6 pp. 97-105

December 2003: Cellzome Signs Research Collaboration with Bayer HealthCare AG

October 2003: Research Collaboration with Johnson & Johnson Pharmaceutical R&D

March 2003: Cellzome Hits Target on Series C Financing

September 2002: Cellzome Appoints Dr. David Brown as President and CEO

January 2002: Cellzome Publishes Novel Approach For The Systematic Use OfProtein Interaction Maps In Drug Discovery In Nature

September 2001: Cellzome Acquires GlaxoSmithKline’s Cell Map Unit

March 2001: Cellzome Closes €34 million ($31 million) Private Placement inSecond Round of Financing